GILD — GILEAD SCIENCES, INC.

—
Nasdaq · Health Care · Biotechnology · CIK 882095 ·
Last close
$170.26
Market Cap
$211.18B
52W High
$176.58
52W Low
$114.81
ADV30
6,357,713
Next earnings
2026-10-29

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 7,803,000,000 6,224,000,000 2,539,000,000 -10,496,000,000 49,362,000,000 3,179,000,000 37,618,000,000
Mar 2026 6,960,000,000 5,515,000,000 2,692,000,000 2,021,000,000 56,278,000,000 7,628,000,000 32,847,000,000
Dec 2025 7,924,000,000 6,300,000,000 2,988,000,000 2,183,000,000 59,023,000,000 7,564,000,000 36,405,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$13,550,000,000
Investing CF
$-10,839,000,000
Financing CF
$-4,647,000,000
CapEx
$-609,000,000
Dividends Paid
$-4,068,000,000
Buybacks
$-1,439,000,000
EPS Diluted TTM
$-3.16
As of
2026-11-01

Balance + Analyst (yfinance extras)

Retained Earnings
$2,200,000,000
Inventory
$1,953,000,000
Receivables
$5,055,000,000
ST Investments
$0
EBIT TTM
$-957,000,000
Pretax Income TTM
$-1,955,000,000
Interest Exp TTM
$998,000,000
Analysts
26

Yahoo Snapshot (yfinance, live)

Total Revenue
$30,987,999,232
EBITDA
$15,351,000,064
Free Cash Flow
$12,642,374,656
Enterprise Value
$231,827,881,984
Total Cash
$6,437,000,192
Total Debt
$26,450,999,296
Shares Out
1,240,338,614
Trailing EPS
$-3.13
Book Value
$10.44
ROE
-22.4%
ROA
14.3%
Div Yield
1.92%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 29,442,000,000 11,701,000,000 8,510,000,000 59,023,000,000 36,405,000,000 22,702,000,000 10,019,000,000
Dec 2024 28,754,000,000 10,596,000,000 480,000,000 58,995,000,000 39,749,000,000 19,330,000,000 10,828,000,000
Dec 2023 27,116,000,000 8,838,000,000 5,665,000,000 62,125,000,000 39,376,000,000 22,833,000,000 8,006,000,000
Dec 2022 27,281,000,000 10,974,000,000 4,592,000,000 63,171,000,000 41,962,000,000 21,240,000,000 9,072,000,000

TTM Snapshot

Revenues TTM
$30,457,000,000
NetIncome TTM
$-3,240,000,000
OpCashFlow TTM
—
Assets (Latest)
$49,362,000,000
Forward EPS
$10.06

Max Pain — expiry 2026-12-18

max pain strike: $90.00 · spot: $168.98 · call oi: 25 · put oi: 1,382
Expected Move to 2026-12-18: ±$12.58 (7.44%) — implied range $156.40 – $181.56 · ATM straddle on $170.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
AMGN AMGEN INC $247.70B $457.93 —
MRNA Moderna, Inc. $82.56B $206.80 —
ARGX ARGENX SE $58.92B $947.52 —
BIIB BIOGEN INC. $37.07B $250.79 —
RVMD Revolution Medicines, Inc. $35.19B $162.69 —

News headlines (Yahoo Finance, 1h cache)

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
2026-11-18 13:00 · Yahoo
iShares Biotechnology ETF (IBB) Buys $16.2 Million More Gilead on Nov. 16
2026-11-18 11:05 · Yahoo
Gilead Sciences Maps Growth Beyond BIKTARVY With HIV, Cancer and Inflammation Drugs
2026-11-17 16:16 · Yahoo
Suffolk Celebrates Completion of Gilead Sciences Research Center With Ribbon Cutting
2026-11-17 16:00 · Yahoo
Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035
2026-11-17 15:00 · Yahoo
Allogeneic Cell Therapy - Global Strategic Business Report 2026: Capitalize on 27.7% CAGR to Capture $2.4B by 2032 with Allogene, Gilead Sciences, Atara and Nkarta
2026-11-17 14:53 · Yahoo
Gilead Sciences Bets on HIV Prevention Growth Despite $1.5 Billion Biktarvy Headwind
2026-11-17 13:12 · Yahoo
What iShares Biotechnology ETF (IBB) Bought: Gilead Leads on Nov. 13
2026-11-17 11:05 · Yahoo
Gilead Sciences (GILD) Grants Royalty Free Ebola Drug Licenses For Lower Income Countries
2026-11-17 01:06 · Yahoo
These 3 Dividend Stocks Have Crushed the Market This Year. Here’s Why They Are Still Buys
2026-11-17 00:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.